Informed Consent Forms Clause Samples

Informed Consent Forms. Any informed consent forms with study subjects under any GBT study or any of its Partner studies for the Product shall include the right to transfer samples, data and information from such study to a third party (such as Roche) if the rights to develop the Product are transferred to such third party.
View SourceView Similar (4)
Informed Consent Forms. Any Informed Consent forms with patients under any River Vision study shall include the right to transfer samples, data and information to Roche.
View SourceView Similar (2)
Informed Consent Forms. Any Informed Consent forms with study subjects under any clinical study run by or on behalf of Company or any of its Partners containing the Product shall include the right to transfer samples, data and information from such study to Roche in the event the Agreement is terminated or rights otherwise revert to Roche.
View Source
Informed Consent Forms. Any Informed Consent forms with study subjects under any PEGA1 study or any of its Partner study containing the Product shall include the right to transfer samples, data and information from such study to Roche.
View Source
Informed Consent Forms. Each Party shall use [*****] to include in its Informed Consent forms with patients under any clinical study for the Product conducted by a Party under this Agreement the right to transfer samples, data and information to the other Party and to any entity designated by such other Party to the extent feasible under Applicable Laws and under a clinical site’s internal policies.
View Source
Informed Consent Forms. The Parties shall use [*****] to include, and to require their Affiliates, sublicensees (as applicable) and any Third Parties acting on behalf of any of the forgoing to include, in each informed consent form with each patient that is a subject in any Clinical Study for the Product conducted by or on behalf of Almirall, its Affiliates or sublicensees (as applicable) under this Agreement, the right to transfer samples, data and information to the other Party and to any entity designated by the other Party to the extent feasible under Applicable Laws and under a clinical site’s internal policies.
View Source
Informed Consent Forms. Sponsor will review and approve all ICF templates and any substantive changes required by the Investigators.
View Source
Informed Consent Forms. The Sponsor hereby directs and authorizes the CRU to act as the Sponsor’s agent with actual authority to enter into and execute for and on behalf of the Sponsor and in the Sponsor’s name a subject informed consent form for each volunteer study performed under the Agreement and a Work Order in accordance with all applicable Regulatory Requirements. The current informed consent form template is available upon request.
View Source
Informed Consent Forms. To the extent permitted by Applicable Law, any Informed Consent forms with study subjects under any CinCor study or any of its Partner study containing any Product shall include the right to transfer samples, data and information from such study to Roche in connection with any termination of this Agreement by Roche pursuant to Sections 19.2, 19.3, 21.8 or by CinCor pursuant to Section 19.4.
View Source

Related to Informed Consent Forms

  • Informed Consent Principal Investigator shall ensure that the ICF approved by Sponsor, IEC and/or RA is signed on behalf of each Trial Subject before the first Trial related procedure starts for the Trial Subject. 8. Informovaný souhlas. Hlavní zkoušející je povinen zajistit, že před zahájením prvních postupů klinického hodnocení u subjektu klinického hodnocení bude jménem každého subjektu klinického hodnocení podepsán formulář informovaného souhlasu schválený zadavatelem, NEK a/nebo RÚ.

  • Required Filings and Consents None of the execution, delivery or performance of this Agreement by the Company, the consummation by the Company of the Offer, the Merger or any other transaction contemplated by this Agreement, or the Company’s compliance with any of the provisions of this Agreement will require (with or without notice or lapse of time, or both) any consent, approval, authorization or permit of, or filing or registration with or notification to, any Governmental Entity, other than (a) the filing and recordation of the Certificate of Merger as required by the DGCL, (b) the Company Stockholder Approval, (c) compliance with any applicable requirements of the HSR Act and other applicable foreign or supranational antitrust and competition laws set forth in Section 4.5 of the Company Disclosure Schedule, (d) compliance with the applicable requirements of the Securities Exchange Act of 1934 (the “Exchange Act”), (e) compliance with the applicable requirements of the Securities Act, (f) compliance with any applicable foreign or state securities or Blue Sky Laws, (g) filings with the United States Securities and Exchange Commission (the “SEC”) as may be required by the Company in connection with this Agreement and the transactions contemplated hereby, (h) such filings as may be required under the rules and regulations of the NYSE and (i) where the failure to obtain such consents, approvals, authorizations or permits of, or to make such filings, registrations with or notifications to any Governmental Entity, individually or in the aggregate, would not reasonably be expected to have a Company Material Adverse Effect.

  • Governmental Filings and Consents All material governmental filings, consents, orders and approvals legally required to be filed or made by the Company for the consummation of the transactions contemplated hereby shall have been made or obtained and shall be in full force and effect.

  • No Conflict; Required Filings and Consents (a) The execution, delivery and performance of this Agreement by the Company do not and will not (i) conflict with or violate the certificate of incorporation or by-laws of the Company, (ii) assuming that all consents, approvals and authorizations contemplated by clauses (i) through (ii) of subsection (b) below have been obtained, and all filings described in such clauses have been made, conflict with or violate any law, rule, regulation, order, judgment or decree applicable to the Company or any of its Subsidiaries or by which its or any of their respective properties are bound, or (iii) except as set forth on Section 3.5(a)(iii) of the Company Disclosure Schedule, result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both would become a default) or result in the loss of a benefit under, or give rise to any right of modification, termination, cancellation, amendment or acceleration of, or result in the creation of any Encumbrances (other than Encumbrances arising out of this Agreement or restrictions imposed by law) upon any of the assets or properties of the Company or any of its Subsidiaries, under any of the terms, conditions or provisions of any written or oral note, bond, mortgage, indenture, contract, binding commitment, agreement, understanding, lease (including the lease of any store, distribution center, warehouse or corporate offices), license, permit or other instrument or obligation (each, a “Contract”) to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries or its or any of their respective properties or assets may be bound. (b) The execution, delivery and performance of this Agreement by the Company and the consummation of the Merger by the Company do not and will not require any consent, approval, authorization or permit of, action by, filing or registration with or notification to, any federal, state, local or foreign legislative, executive or regulatory (including stock exchange) authority, agency, court, commission, or other governmental body (each, a “Governmental Entity”), except for (i) the state securities, takeover, tender offer and “blue sky” laws listed on Section 3.5(b) of the Company Disclosure Schedule, and (ii) the filing with the Office of the Secretary of State of the State of Delaware of the Certificate of Merger as required by the DGCL.

  • Deemed Consent The Series 2012-1 Noteholders will be deemed to have consented to any amendment to any Related Document that changes the definition of “Rating Agency Condition” in such Related Document to match the definition of “Rating Agency Condition” in this Indenture Supplement.